Thursday, May 11, 2017 10:56:33 AM
You discussed nothing that was not already released numerous times through news on brokerage web sites. You refused and stated numerous times that you cannot discuss business developments about partnerships because they were not completed. Than you wait to schedule a conference call when those developments are completed and can be discussed.. In other words you truly failed to discuss as a shareholder anything to do with financing near future or current cash flow needs whether through a stock offering or a partnership that could move company more rapidly forward in the commercialization of products. You did not discuss another area or potential product of statins for alzheimer disease that company states they have.
Why did you have this conference call? Very shallow and empty information shared and very vague. You congratulated yourself numerous times for going it alone on phase 1,2 and 3 trials and not needing help form other companies or financial partnerships.
You stated that applications for Country approvals could take 1 year or longer before Prostate pharm. could be moved forward for commercialization.
So I ask you why the conference call to share anything that was new that would give shareholders (as investors in your company)a glimmer of enthusiasm in the 6-9 12 month future to stay currently as investors.
A very poorly organized conference call that was unnecessary and shows why start-up companies need professional alliances to tell their story in a more positive light. You are a publically traded company and shareholders who are investors should be treated better than what you presented yesterday. Very amateurish to listen to your inability to enlighten about the financial future aspects of NYMX. I'll buy you a head-set for your next conference call and hold-off on that next conference call when you can spend time givng out information and not using the majority of conference call to tell us what you cannot say to us.
Recent NYMXF News
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 09/25/2023 08:04:15 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 08/14/2023 07:52:14 PM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM